You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Moodys
Boehringer Ingelheim
Baxter
Mallinckrodt

Last Updated: April 7, 2020

DrugPatentWatch Database Preview

Gadofosveset trisodium - Generic Drug Details

» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for gadofosveset trisodium and what is the scope of freedom to operate?

Gadofosveset trisodium is the generic ingredient in one branded drug marketed by Lantheus Medcl and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Gadofosveset trisodium has forty-three patent family members in twenty-six countries.

Summary for gadofosveset trisodium
International Patents:43
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Bulk Api Vendors: 4
Clinical Trials: 6
Formulation / Manufacturing:see details
DailyMed Link:gadofosveset trisodium at DailyMed
Recent Clinical Trials for gadofosveset trisodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Paul FinnPhase 4
Maastricht University Medical CenterPhase 4
Dutch Cancer SocietyN/A

See all gadofosveset trisodium clinical trials

US Patents and Regulatory Information for gadofosveset trisodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 DISCN No No   Start Trial   Start Trial Y   Start Trial
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 DISCN No No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for gadofosveset trisodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008   Start Trial   Start Trial
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008   Start Trial   Start Trial
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008   Start Trial   Start Trial
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008   Start Trial   Start Trial
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for gadofosveset trisodium

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0806968 SPC 037/2006 Ireland   Start Trial SPC 037/2006: 20070528, EXPIRES: 20201002
0806968 300253 Netherlands   Start Trial 300253, 20160116, EXPIRES: 20201002
0806968 CA 2007 00016 Denmark   Start Trial
0806968 SPC/GB07/011 United Kingdom   Start Trial PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
0806968 PA2007003,C0806968 Lithuania   Start Trial PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REGISTRATION NO/DATE: EU/1/05/313/001, 2005 10 05 EU/1/05/313/002, 2005 10 05 EU/1/05/313/003, 2005 10 05 EU/1/05/313/004, 2005 10 05 EU/1/05/313/005, 2005 10 05 EU/1/05/313/006, 2006 10 05 EU/1/05/313/007, 2005 10 05 EU/1/05/313/008, 2005 10 05 EU/1/05/313/00 2005100
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Moodys
Boehringer Ingelheim
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.